ABBV-011
- Generic Name
- ABBV-011
- Brand Names
- -
- Drug Type
- Biotech
- Chemical Formula
- -
- CAS Number
- -
- Unique Ingredient Identifier
- -
- Background
ABBV-011 is an antibody-drug conjugate of humanized, cysteine-engineered IgG1 monoclonal antibody targeting seizure-related 6 homolog conjugated to N-acetyl-gamma-calicheamicin.
- Associated Conditions
- -
- Associated Therapies
- -
A Study of ABBV-011 Alone and in Combination With Budigalimab (ABBV-181) in Participants With Relapsed or Refractory Small Cell Lung Cancer
- First Posted Date
- 2018-08-21
- Last Posted Date
- 2024-02-09
- Lead Sponsor
- AbbVie
- Target Recruit Count
- 132
- Registration Number
- NCT03639194
- Locations
- 🇺🇸
UH Cleveland Medical Center /ID# 207561, Cleveland, Ohio, United States
🇺🇸The Ohio State University /ID# 207552, Columbus, Ohio, United States
🇺🇸Highlands Oncology Group, PA /ID# 207176, Springdale, Arkansas, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.
© Copyright 2024. All Rights Reserved by MedPath